Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Biogen's (BIIB) Aducanumab Appears Further De-Risked - Jefferies
September 2, 2016 7:44 AM EDTJefferies analyst Brian Abrahams saying Biogen's (NASDAQ: BIIB) aducanumab appears to be further de-risked based tidbit tucked away at the very brief PR the company issued yesterday evening on Fast Track status.
"... we believe new data from the ph.Ib dose titration arms is confirming aducanumab's efficacy observed in the prior arms, helping additionally de-risk the program," Abrahams said.
Abrahams expects upside for shares on this development.
The analyst notes a clear suggestions... More
